麦迪卫康(02159.HK)2020年净利同比增长0.91%至2104.2万元
格隆汇 3 月 26日丨麦迪卫康(02159.HK)公告，截至2020年12月31日止年度的全年业绩，收入人民币(下同)4.32亿元，同比增长1.20%；公司拥有人应占溢利2104.2万元，同比增长0.91%；基本每股盈利14.03分。
在2020年初，集团透过麦迪卫康医加医疗平台发现数百万卒中患者因新冠肺炎疫情爆发而无法亲身前往医院就医或复诊，立即与中国卒中学会携手共同开展"共抗疫情－健康守护者行动"，配合诊断、救治工作，服务数百万无法亲身前往医院就医的脑血管病患者，保障他们依然能享受到常规及及时的诊疗服务，帮助和指导高危人群预防卒中发生。
2020年下半年，麦迪卫康与石药集团有限公司达成战略合作，为国内卒中患者推出"卒中患者标准化院外管理项目"，提供出院后谘询、随访、复诊检查、电子处方及送药到家等一站式院外管理方案，目前已复盖全国十个省份并不断扩展，另已搭建卒中患者标准化院外管理体系，满足卒中患者"用药＋复诊＋检查"的持续性专业诊疗需求。
为满足广大医生对学术内容、持续教育的需求和广大患者对疾病知识、健康宣教内容的需求，麦迪卫康与非政府组织("NGO组织")合作，开展线上、线下医生教育活动及患者教育活动。
其中，中国卒中学会第六届学术年会暨天坛国际脑血管病会议2020(CSA&TISC2020)以线上+线下的形式举办，共复盖医生约15万人次。在10月29日世界卒中日前后，集团通过其医疗平台开展线上免费健康谘询和义诊活动，协助中国卒中学会开展了面向全国的"2020年世界卒中日全国健康科普志愿行动"。互联网医疗服务是集团重要的发展方向。
优质的医生资源是提供互联网医疗服务能力的保证，集团通过其专供患者使用的微信公众号麦迪卫康医加及专供医生使用的移动应用程式医加医生端获取专业及优质的医生资源，为患者提供疾病管理服务；截至2020年12月31日，医加医生端的医生注册用户数达到18,781人，较2019年增长逾60倍，而麦迪卫康医加的患者用户数达25,874人，较2019年增长逾20倍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
